LOVASTATIN INDUCES GROWTH-INHIBITION AND APOPTOSIS IN HUMAN-MALIGNANT GLIOMA-CELLS
LOVASTATIN INDUCES GROWTH-INHIBITION AND APOPTOSIS IN HUMAN-MALIGNANT GLIOMA-CELLS
复制标题
DOI：
10.1006/bbrc.1994.2861
复制
发表时间：
1994-12-30
影响因子：
3.1
通讯作者：
LAW, RE
中科院分区：
文献类型：
--
作者：
JONES, KD;COULDWELL, WT;LAW, RE
竞争性的HMG-CoA还原酶抑制剂洛伐他汀已被证明可以抑制多种非胶质瘤肿瘤细胞系的生长并诱导其形态变化。本研究评价了该药对人恶性胶质瘤细胞系A172和U87-MG生长和存活的影响。用细胞增殖实验研究了药物的反应，结果显示明显的剂量依赖性生长抑制。在72小时内用100毫微米的洛伐他汀治疗会导致DNA降解成核小体大小的片段，这是细胞凋亡的特征。我们的数据表明，HMG-CoA还原酶抑制剂，如洛伐他汀，值得进一步研究，作为治疗恶性胶质瘤的潜在治疗药物。(C)1994年学术出版社。
The competitive HMG-CoA reductase inhibitor lovastatin has been shown to suppress growth and induce morphological changes in a variety of non-glioma tumor cell lines. This study assesses the effects of this agent on the growth and survival of the human malignant glioma cell lines A172 and U87-MG. The response to the drug was investigated using a cell proliferation assay which revealed significant dose-dependent growth inhibition. Treatment with as little as 100 nM lovastatin over a period of 72 hours led to DNA degradation into nucleosome-sized fragments characteristic of apoptosis. Our data suggest that HMG-CoA reductase inhibitors such as lovastatin merit further investigation as potential therapeutic agents for the treatment of malignant gliomas. (C) 1994 Academic Press, Inc.